Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Tg Therapeutics (TGTX) over the last 6 years, with Q3 2025 value amounting to $2.43.
- Tg Therapeutics' EPS (Weighted Average and Diluted) rose 1205000.0% to $2.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.78, marking a year-over-year increase of 262727.27%. This contributed to the annual value of $0.15 for FY2024, which is 6666.67% up from last year.
- Latest data reveals that Tg Therapeutics reported EPS (Weighted Average and Diluted) of $2.43 as of Q3 2025, which was up 1205000.0% from $0.17 recorded in Q2 2025.
- Tg Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $2.43 for Q3 2025, and its period low was -$0.71 during Q4 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.26 (2022), whereas its average is -$0.08.
- In the last 5 years, Tg Therapeutics' EPS (Weighted Average and Diluted) plummeted by 9726.03% in 2024 and then surged by 1205000.0% in 2025.
- Over the past 5 years, Tg Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.71 in 2021, then increased by 19.84% to -$0.57 in 2022, then skyrocketed by 82.46% to -$0.1 in 2023, then soared by 250.0% to $0.15 in 2024, then surged by 1520.0% to $2.43 in 2025.
- Its EPS (Weighted Average and Diluted) was $2.43 in Q3 2025, compared to $0.17 in Q2 2025 and $0.03 in Q1 2025.